
Artivion (AORT) Stock Forecast & Price Target
Artivion (AORT) Analyst Ratings
Bulls say
Artivion is poised for significant growth through new product launches, international expansion, and its strong pipeline. The company's focus on cardiac and vascular solutions has been driving consistent revenue growth, with a strong gross margin of 90%. Despite short-term challenges, AORT's long-term outlook is positive, and the recent decline in share price presents an undervalued opportunity for investors. With a diversified revenue mix and a solid base business, AORT is well-positioned for continued success.
Bears say
Artivion is facing a negative outlook due to expected slowed revenue growth in the upcoming years stemming from weak product launches and poor international expansion. The company's reliance on the Medical Devices segment, specifically AMDS, for growth may be hindered by delays in FDA approval and limited addressable market. Additionally, Artivion faces risks such as competition from larger players, regulatory and reimbursement uncertainties, and exchange risk from international sales.
This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.
Artivion (AORT) Analyst Forecast & Price Prediction
Start investing in Artivion (AORT)
Order type
Buy in
Order amount
Est. shares
0 shares